Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data
Catharine I. Paules, Shannon Gallagher, Rekha R. Rapaka, Richard T. Davey, Sarah B. Doernberg, Robert Grossberg, Noreen A. Hynes, Philip O. Ponce, William R. Short, Jocelyn Voell, Jing Wang, Otto O. Yang, Cameron R. Wolfe, David Chien Lye, Lori E. Dodd, Constance A. Benson
Abstract
This post hoc analysis of the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1 (ACTT-1) shows a treatment effect of remdesivir (RDV) on progression to invasive mechanical ventilation (IMV) or death. Additionally, we create a risk profile that better predicts progression than baseline oxygen requirement alone. The highest risk group derives the greatest treatment effect from RDV.
Topics & Concepts
MedicinePost-hoc analysisCoronavirus disease 2019 (COVID-19)Mechanical ventilationCoronavirusSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseasePost hocCohort2019-20 coronavirus outbreakIntensive care medicineInternal medicineVirologyInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesRespiratory Support and MechanismsLong-Term Effects of COVID-19